17β-Estradiol Reduces Demyelination in Cuprizone-fed Mice by Promoting M2 Microglia Polarity and Regulating NLRP3 Inflammasome. (21st May 2021)

• Record Type: Journal Article
• Authors: Aryanpour, Roya; Zibara, Kazem; Pasbakhsh, Parichehr; Jame'ei, Seyyed Behnamodin; Namjoo, Zeinab; Ghanbari, Amir; Mahmoudi, Reza; Amani, Showan; Kashani, Iraj Ragerdi
• Is Part Of: Neuroscience. Volume 463(2021)
• Page Start: 116
• Page End: 127
• Publication Date: 2021-05-21
• Subjects: CNS central nervous system -- CPZ cuprizone -- E2 17β-estradiol -- ER-β estrogen receptor-beta -- MS multiple sclerosis -- MWM Morris Water Maze -- NOD nucleotide-binding oligomerization domain -- OPC oligodendrocyte precursor cells -- SCI spinal cord injury; 17β-estradiol -- microglia -- neuroinflammation -- inflammasome -- multiple sclerosis; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2021.03.025
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: Estrogen produces polarization and neuroinflammation on microglia. 17β-Estradiol therapy caused a decrease in demyelination levels and axonal injury. 17β-Estradiol affects Nlrp3 inflammasome and IL-18, a downstream product of NLRP3. 17β-Estradiol therapy caused a shift in microglial phenotype from an M1 to M2. Abstract: Estrogen produces a beneficial role in animal models of multiple sclerosis (MS). The effect of 17β-estradiol therapy on microglia polarization and neuroinflammation in the corpus callosum of the cuprizone-induced demyelination model has not been elucidated. In this study, mice were given 0.2% cuprizone (CPZ) for 5 weeks to induce demyelination during which they received 50 ng of 17β-estradiol (EST), injected subcutaneously in the neck region, twice weekly. Data revealed that treatment with 17β-estradiol therapy (CPZ+EST) improved neurological behavioral deficits, displayed by a significant reduction in escape latencies, in comparison to untreated CPZ mice. Also, administration of 17β-estradiol caused a decrease in demyelination levels and axonal injury, as demonstrated by staining with Luxol fast blue, immunofluorescence to myelin basic protein, and transmission electron microscopy analysis. In addition, at the transcriptional level in the brain, mice treated with 17β-estradiol (CPZ+EST) showed a decrease in the levels of M1-assosicted microglia markers (CD86, iNOS and MHC-II) whereas M2-associated genes (Arg-1, CD206 and Trem-2) were increased, compared to CPZ mice. Moreover, administration of 17β-estradiol resulted in a significant reduction (∼3-fold) in transcript levels of NLRP3 inflammasome and its downstream product IL-18, compared to controls. In summary, this study demonstrated for the first time that exogenous 17β-estradiol therapy robustly leads to the reduction of M1 phenotype, stimulation of polarized M2 microglia, and repression of NLRP3 inflammasome in the corpus callosum of CPZ demyelination model of MS. The positive effects of 17β-estradiol on microglia and inflammasome seems to facilitate and accelerate the remyelination process.